Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
August 23, 2017Asterias Biotherapeutics Opens Additional Clinical Site for AST-OPC1 SCiStar Study
FREMONT, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Washington University School of Medicine in St. Louis, MO, has been added as a clinical site in the company’s ongoing SCiStar Phase 1/2a clinical trial of AST-OPC1, a stem-cell derived investigational therapy, in patients with severe cervical spinal cord injury (SCI). There are now nine clinical sites enrol... 
Printer Friendly Version
August 14, 2017OncoCyte Confirms Launch Plans for Lung Cancer Diagnostic Test; Reports Progress Toward CLIA Lab Licensing and Second Quarter 2017 Financial Results
- Introduces Lung Cancer Diagnostic Branding- -Conference Call Today at 4:30 pm ET- ALAMEDA, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported the following developments: Financial results for the quarter ended June 30, 2017,  Planned expansion of the senior management team by adding a Vice President of Sales and full time Chief Financial Officer, Branding for ... 
Printer Friendly Version
August 14, 2017Asterias Biotherapeutics Reports Second Quarter Financial Results and Reviews Recent Clinical Progress and Corporate Developments
- Achieved meaningful progress with key clinical programs; multiple milestones anticipated during remainder of 2017- - Conference Call and Webcast Today, August 14, at 4:30 p.m. ET - FREMONT, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today reported financial and operational results for the quarter ended June 30, 2017, as well as recent corporate progress. “We made signific... 
Printer Friendly Version
August 14, 2017Asterias Announces Major AST-VAC2 Development Milestone: First cGMP-Compliant Lot Successfully Manufactured to Support First Clinical Study of AST-VAC2
Successful Production Run Provides Sufficient AST-VAC2 Supply to Initiate Clinical Study in Non-Small Cell Lung Cancer Expected to Begin in Second Half of 2017 FREMONT, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Cancer Research UK, supported by Asterias technical personnel, has successfully completed manufacture of the first cGMP (current Good Manufacturing... 
Printer Friendly Version
August 09, 2017Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial
Enrollment for entire SCiStar study expected to be completed by end-2017 FREMONT, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced enrollment and dosing of the first patient in the fifth and final cohort in the company’s ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in motor complete cervical spinal cord injury (SCI). This cohort will dose between five and eig... 
Printer Friendly Version
August 08, 2017Former Quadriplegic Enrolled in Asterias’ SCiStar Study to Throw Ceremonial First Pitch at Major League Baseball Game
FREMONT, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST) today announced that Lucas Lindner of Eden, Wisconsin, a quadriplegic patient who has regained functional use of his fingers, hands and lower arms after receiving the company’s investigational stem cell therapy for complete cervical spinal cord injury, AST-OPC1, will throw out the ceremonial first pitch of a Major League Baseball game in Milwaukee on Sunday, August 13th. “Lucas has been an inspi... 
Printer Friendly Version
August 07, 2017Asterias Biotherapeutics to Present at Canaccord Genuity Growth Conference on August 10, 2017
FREMONT, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Mike Mulroy, President and Chief Executive Officer, will present at the Canaccord Genuity 2017 Growth Conference at the InterContinental Boston in Boston, MA. Asterias’ presentation is scheduled for Thursday, August 10, 2017, at 10:30 a.m. Eastern Time. A live webcast of the presentation will be accessib... 
Printer Friendly Version
August 07, 2017OncoCyte Latest Lung Cancer Diagnostic Test Data Accepted for Slide Presentation at CHEST 2017 Annual Meeting
ALAMEDA, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests to support the early detection of cancer, announced today that data from the Company’s latest confirmatory lung cancer diagnostic research have been accepted for a slide presentation at the American College of Chest Physician’s CHEST 2017 annual meeting. The meeting will be held in Toronto, Ontario, Canada, from October 28 to November 1, 2017.   The presentation wil... 
Printer Friendly Version
August 03, 2017Asterias Biotherapeutics Opens Two Additional Clinical Sites for AST-OPC1 SCiStar Study
New sites include Thomas Jefferson University Hospital and UC San Diego Health FREMONT, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company pioneering the field of regenerative medicine, today announced that two additional clinical sites have opened to enroll subjects for the company’s ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in complete cervical spinal cord injury (SCI). The additional clinical sites include: Thomas Je... 
Printer Friendly Version
July 31, 2017Asterias Biotherapeutics to Report Second Quarter Results on August 14, 2017
FREMONT, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release second quarter 2017 financial and operational results on Monday, August 14, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast on August 14, 2017 at 4:30 p.m. Eastern / 1:30 p.m. Pacific. For both "listen-only" participants and... 
Printer Friendly Version
July 26, 2017OncoCyte to Report Second Quarter Financial Results on August 14, 2017
ALAMEDA, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended June 30, 2017, on Monday, August 14, 2017, after the close of the U.S. financial markets. The Company will host a conference call on Monday, August 14, 2017, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results along with rece... 
Printer Friendly Version
July 25, 2017OncoCyte Receives $5.74 Million in Proceeds from Exercise of Warrants
ALAMEDA, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $5.74 million through the cash exercise of 1,766,923 common stock purchase warrants.  Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued as part of a $10.5 million financing completed in August 2016 and would have otherwise been exercisable un... 
Printer Friendly Version
July 24, 2017OncoCyte Analytical Validation Study of its Lung Cancer Diagnostic Test Confirms Previously Published Results
- Abstract to Present Complete Study Findings Submitted to a Scientific Conference - - Final Stage of Development Commences- ALAMEDA, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests to assist in the early detection of cancer, announced today that it has successfully completed the Analytical Validation study of its liquid biopsy lung cancer diagnostic test. The results are consistent with the d... 
Printer Friendly Version
July 17, 2017Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort
Twenty patients have been enrolled in SCiStar study 20 million cell dose escalation cohort to inform future trial design Dosing fifth patient in this cohort triggers $1.5 million grant payment FREMONT, Calif., July 17, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced completion of enrollment and dosing of the AIS-A 20 million cell cohort in the company's ongoing SCiStar Phase 1/2a ... 
Printer Friendly Version
July 12, 2017Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
First enrolled cohort comprised of patients with motor complete, sensory incomplete paralysis FREMONT, Calif., July 12, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced completion of enrollment and dosing of the AIS-B 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in complete cervical spinal cord injury (SCI). In this cohort, five patients w... 
Printer Friendly Version
July 10, 2017Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study
Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials FREMONT, Calif., July 10, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's amendment to the clinical research protocol for its ongoing AST-OPC1 SCiStar Phase 1/2a clinica... 
Printer Friendly Version
June 26, 2017OncoCyte Corporation Added to Russell 3000® Index and Russell 2000® Index
ALAMEDA, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, has been added to the broad U.S. market Russell 3000® Index and the small-cap Russell 2000® Index as part of Russell Investments' annual reconstitution of its stock indexes. The addition to both indexes is effective at the opening of U.S. markets today. “OncoCyte’s inclusion in the Russell 3000 and 2000 ... 
Printer Friendly Version
June 15, 2017OncoCyte Reports Successful Completion of Follow on Breast Cancer Diagnostic Study
ALAMEDA, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it has successfully completed a follow on study of its breast cancer diagnostic test. The study, known as NICE-BC (Non-Invasive Confirmatory dEtection (of) Breast Cancer, has confirmed the findings of OncoCyte’s previous breast cancer study, which was presented at the San Antonio Breast Cancer Symposium (SABCS) ... 
Printer Friendly Version
June 13, 2017Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias' AST-OPC1
Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side FREMONT, Calif., June 13, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that new 9-month follow-up data from the AIS-A 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial shows three of six (50%) pat... 
Printer Friendly Version
June 12, 2017OncoCyte Corporation Set to Join Russell 3000® Index
ALAMEDA, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, announced today that the Company is set to join the broad-market Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the U.S. market opens on June 26. “The preliminary addition of OncoCyte to the Russell 3000 Index is a testament to the progress we have mad... 
Printer Friendly Version
June 08, 2017Asterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting
FREMONT, Calif., June 8, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will present new 9-month efficacy and safety data on those AIS-A patients treated with 10 million cells of AST-OPC1 in the company's ongoing SCiStar Phase 1/2a study in complete cervical spinal cord injury. This update will take place during a pre-meeting workshop and a poster session at the International Soci... 
Printer Friendly Version
May 23, 2017Asterias Biotherapeutics Announces Top Leadership Transition
-Steve Cartt to transition out as President & CEO, remain on the Board of Directors- -Michael Mulroy appointed President & CEO effective June 26, 2017- -Katy Spink, Ph.D., promoted to Executive Vice President & COO- -Conference Call Today at 4:45pm ET- FREMONT, Calif., May 23, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that Michael Mulroy has been appointed... 
Printer Friendly Version
May 22, 2017OncoCyte Presents Positive Lung Cancer Blood Test Data at American Thoracic Society
- Continues Plans to Commercialize Lung Cancer Diagnostic Test in 2017 - - Conference Call Today at 4:30 PM Eastern Daylight Time - ALAMEDA, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests for the early detection of cancer, today reported positive new results in its development of a highly-accurate blood-based lung cancer diagnostic. Data from a multi-site study further validate the test’s comm... 
Printer Friendly Version
May 11, 2017Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
-Continued positive interim efficacy and safety results reported during the quarter; multiple data readouts on the efficacy and safety of AST-OPC1 anticipated during 2017- - Conference Call and Webcast Today, May 11, at 4:30 p.m. ET - FREMONT, Calif., May 11, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today reported financial and operational results for the quarter ended March 31, 2017, as well... 
Printer Friendly Version
May 11, 2017New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
-MRI scans are consistent with durable engraftment of AST-OPC1 cells in the damaged area of the spinal cord and show the potential of AST-OPC1 to reduce spinal cord tissue deterioration after severe spinal cord injury- -These disease-modifying aspects of AST-OPC1 may carry long term benefits related to both recovery and maintenance of motor and sensory function- FREMONT, Calif., May 11, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering ... 
Printer Friendly Version
May 09, 2017OncoCyte Executive to Address Next Generation Dx Summit on Successful Reimbursement Strategies for Diagnostic Tests
ALAMEDA, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that William Haack, Vice President of Market Access, will address the Next Generation Dx Summit 2017 on successful reimbursement strategies for diagnostic tests. Mr. Haack’s presentation, titled “The Reimbursement Crisis for Molecular Diagnostics is a Myth”, is being given on Wednesday, August 16, 2017, at 8:55 a.m. E... 
Printer Friendly Version
May 04, 2017OncoCyte Establishes Medical Advisory Committee to Enhance Development Strategy for Lung Cancer Diagnostics
ALAMEDA, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests to aid in the early detection of cancer, today announced that a Medical Advisory Committee of lung cancer specialists has been established to provide guidance to OncoCyte’s senior management team on issues relating to lung cancer diagnosis.  The Committee is expected to provide advice in a number of areas, including unmet clinical needs, the profiles of pa... 
Printer Friendly Version
May 04, 2017Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017
FREMONT, Calif., May 4, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release first quarter 2017 financial and operational results on Thursday, May 11, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast on May 11, 2017 at 4:30 p.m. Eastern / 1:30 p.m. For both "listen-only" participants and those participants w... 
Printer Friendly Version
May 03, 2017Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury
FREMONT, Calif., May 3, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that data from its AST-OPC1 clinical program for severe cervical spinal cord injury will be presented during the Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting, being held in Washington, D.C. during May 10-13, 2017. "The ASGCT decision to include a presentation o... 
Printer Friendly Version
April 28, 2017OncoCyte Continues to Make Progress Towards Commercialization; Reports First Quarter 2017 Results
Expects to Report Results of 300 Patient R&D Validation Study on May 22, 2017 Conference Call Scheduled for May 22, 2017 at 4:30pm ET ALAMEDA, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, today reported its financial results for the quarter ended March 31, 2017.  In addition, OncoCyte announced it will conduct an investor call on May 22, 2017 at 4:30pm ET/1:30 pm... 
Printer Friendly Version
April 26, 2017Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
-57% of AML patients treated with AST-VAC1, including high-risk patients, had prolonged relapse-free survival- FREMONT, Calif., April 26, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the results from its completed Phase 2 clinical trial of AST-VAC1 are now available online in Cancer,  a leading peer-reviewed journal of the American Cancer Society. The study publication ... 
Printer Friendly Version
April 25, 2017Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Cervical Spinal Cord Injury
FREMONT, Calif., April 25, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) today announced that following a regularly scheduled interim review of safety data from its SCiStar Phase 1/2a clinical trial of AST-OPC1 for acute spinal cord injury, the study's Data Monitoring Committee (DMC) recommended continuation of enrollment for the 10 million cell and 20 million cell dose cohorts in the study, as planned. "The DMC's recommendation to continue our SCiStar study without modi... 
Printer Friendly Version
March 28, 2017Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
- Recent clinical trial results highlight the potential for AST-OPC1 to help patients with complete paralysis recover arm, hand and finger function - - Company resources, improved significantly from a year ago, are now primarily focused on developing AST-OPC1 for the treatment of cervical spinal cord injuries - - Conference Call and Webcast Today, March 28, at 4:30 p.m. ET - FREMONT, Calif., March 28, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology c... 
Printer Friendly Version
March 21, 2017OncoCyte Submits Application for CLIA Certification of its Laboratory
Achieving Certification is Key Step for Planned Commercial Launch in the Second Half of 2017 ALAMEDA, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, has submitted its application for CLIA certification of its laboratory, the next step towards its objective of launching the Company’s first commercial product, a lung cancer diagnostic test, in the second half of 2017.  ... 
Printer Friendly Version
March 21, 2017Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
-Newly reported data on sixth and final patient in cohort further confirms previously announced improvements in hand and arm function following dosing- FREMONT, Calif., March 21, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, reported that including the sixth and final patient in the AIS-A 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial has further confirmed previousl... 
Printer Friendly Version
March 07, 2017Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
FREMONT, Calif., March 7, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release fourth quarter and full year 2016 financial and operational results on Tuesday, March 28, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast on March 28, 2017 at 4:30 p.m. Eastern / 1:30 p.m. For both "listen-only" participants and those par... 
Printer Friendly Version
March 06, 2017OncoCyte Reports Successful Results of Lung Cancer Diagnostic Test Study; Targets 2017 Product Launch to Address $4 Billion-plus Market
Data from the Study Exceed Levels Believed Necessary for a Commercially Successful Test Conference Call Scheduled for Today at 4:30 PM ET ALAMEDA, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, today reported the successful completion of a critical step in the development of its lung cancer diagnostic test. While the key performance metrics of its diagnostic cannot... 
Printer Friendly Version
March 01, 2017OncoCyte Corporation to Present at Cowen and Company 37th Annual Health Care Conference
ALAMEDA, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will begin at 9:20 a.m. ET on Wednesday, March 8th, 2017 at the Boston Marriott Copley Place. Plea... 
Printer Friendly Version
February 27, 2017OncoCyte Corporation Reports Fourth Quarter and Full Year 2016 Financial Results
Enters into New Credit Facility with Silicon Valley Bank Conference Call Scheduled for Monday, March 6, 2017 at 4:30 PM ET ALAMEDA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive, ”liquid biopsy” tests to aid in the early detection of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2016. OncoCyte also reported that it has entered into a secured loan agreement with Silicon Val... 
Printer Friendly Version
February 21, 2017OncoCyte Receives $2 Million in Proceeds from Early Exercise of Warrants
Completes Sample Collection and Processing for the 300-Patient Study of its Lung Cancer Diagnostic Test ALAMEDA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $2,031,250 through the early exercise of 625,000 common stock purchase warrants.  Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued durin... 
Printer Friendly Version
February 13, 2017OncoCyte Corporation to Present at the 19th Annual BIO CEO & Investor Conference and the 2017 Disruptive Growth & Healthcare Conference
ALAMEDA, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th, at 10:30 a.m. ET, where OncoCyte is also being recognized and honored as the Buzz of BIO winner in the “diagnostics ... 
Printer Friendly Version
February 03, 2017Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
- Warrant extension follows positive recent update on further motor function improvements observed in SCiStar study patients dosed with AST-OPC1 - - Cash position significantly improved from the same time last year - FREMONT, Calif., Feb. 3, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced the company is extending the expiration date of certain warrants. The decision to ex... 
Printer Friendly Version
January 27, 2017OncoCyte Wins Buzz of BIO for the 2017 BIO CEO & Investor Conference
ALAMEDA, Calif., Jan. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that the Biotechnology Innovation Organization (BIO) has recognized OncoCyte Corporation as the Buzz of BIO winner in the “diagnostics and beyond category” for the 2017 BIO CEO & Investor Conference taking place February 13–14 at the Waldorf Astoria in New York. Nominated and selected by an online vote, contest winners are... 
Printer Friendly Version
January 24, 2017Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
-Management to discuss results on conference call today at 5:00 p.m. Eastern / 2:00 p.m. Pacific- -SCiStar lead investigator Richard Fessler, MD, and John Steeves, Ph.D., Co-Chair of the Spinal Cord Outcomes Partnership Endeavor (SCOPE), will join Asterias management on the call- FREMONT, Calif., Jan. 24, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced positive efficacy... 
Printer Friendly Version
January 24, 2017OncoCyte to Present Interim Data from Its Lung Cancer Diagnostic Test Study at the American Thoracic Society Conference May 22, 2017
ALAMEDA, Calif., Jan. 24, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that its abstract on interim data from the Company’s lung cancer diagnostic test study has been selected for presentation in a poster discussion session at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C.  The discussion will be led by Dr. Anil Vachani, an Associate Professor of Medicin... 
Printer Friendly Version
January 04, 2017OncoCyte Provides Updated Timelines on Diagnostic Test Development and Commercialization Plans
Breast Cancer Test Development Three to Six Months Ahead of Schedule; Commercial Launch Possible in Mid to Late 2018 Lung Cancer Test Development Two to Three Months Behind Schedule; Commercial Launch Planned for Second Half of 2017 ALAMEDA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine based tests for the early detection of cancer, today provided an update on the development of its product portfolio that c... 
Printer Friendly Version